Ascendis Pharma Reports Q2 Net Loss of €38.9 Million, Down from €109.4 Million in Same Period Last Year.

Ascendis Pharma reported a net loss of €38.9 million in Q2 2025, compared to a net loss of €109.4 million in the same period last year. The company's loss per share was €0.64 basic and €0.82 diluted.

Ascendis Pharma (NASDAQ: ASND) reported its second-quarter (Q2) 2025 financial results, showing significant improvements in revenue and operational efficiency compared to the same period last year. The company's total revenue for Q2 2025 was €158.0 million, up from €36.0 million in Q2 2024, representing a substantial 339% increase. This growth was primarily driven by commercial products, with YORVIPATH (palopegteriparatide) contributing €103.0 million and SKYTROFA (lonapegsomatropin) adding €50.7 million [1].

Despite the significant increase in revenue, Ascendis Pharma reported a net loss of €38.9 million for Q2 2025, compared to a net loss of €109.4 million in the same period last year. This represents a 64.4% reduction in net loss, despite higher operating expenses. The company's loss per share was €0.64 basic and €0.82 diluted [1].

The reduction in net loss can be attributed to improved operational efficiency and commercial success. Research and development (R&D) expenses decreased by 13.8% to €72.0 million, primarily due to the maturity of clinical trials in their growth disorders portfolio. However, selling, general, and administrative (SG&A) expenses increased by 44.8% to €107.6 million, reflecting ongoing commercial expansion efforts [1].

Ascendis Pharma maintained a strong cash position of €494 million as of June 30, 2025, down from €560 million at the end of 2024. This 11.8% cash burn over six months appears reasonable given their commercial expansion and ongoing R&D investments [1].

The company's pipeline developments position it for continued growth. The FDA's priority review of TransCon CNP (navepegritide) for children with achondroplasia, with a PDUFA date of November 30, 2025, and SKYTROFA's U.S. approval for adult growth hormone deficiency treatment, are key milestones. Additionally, the promising interim results from the COACH trial for combination therapy further strengthen their growth disorders franchise [1].

References:
[1] https://www.stocktitan.net/news/ASND/ascendis-pharma-reports-second-quarter-2025-financial-uf8xwa0fvvkh.html